medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2005, Number 3

<< Back Next >>

Rev Mex Urol 2005; 65 (3)

Supressor gene of P53 tumor as recurrence and progression factor in bladder cancer

Morales MG, Soel EJ, Maldonado VR, Solares SM, Viveros JM, Parraguirre S, Calderón FF

Language: Spanish
References: 20
Page: 183-191
PDF size: 74.69 Kb.


ABSTRACT

Background. Bladder cancer is the second most frequent neoplasm of the urinary system, and the fifth cause of death in males. In Mexico there was an increase from 11 to 14 x 100,000 inhabitants from 1985 to 1994. Several researchers have studied the effect and role of the cellular cycle regulating proteins. The p53 suppressor gene, frequently implicated in several tumors plays a still debated role in bladder cancer. Objective. The purpose of this study is to determine of p53 can be used as a prognostic factor in transitional cell carcinoma of the bladder. Material and methods. Open, retrospective, transversal, comparative and observational study. Patients from the last 11 years with diagnosis of bladder cancer, who received treatment, were included. The variables analyzed were: age, gender, tumor size, pathologic stage, nuclear stage, positivity to p53 immunohystochemistry, recurrence and progression. Statistic analysis was realized using descriptive statistics, Odds ratio and Chi square. Results. 63 patients were studied (44 male and 19 female), 58% had superficial tumors and 42% were invasive. Immunohystochemistry of p53 was positive in 45 patients out of 63 (71%). Recurrence and progression were more frequent in p53 positive patients. Conclusions. P53 positivity can be used as a predictor factor of recurrence and progression in transitional bladder cancer.


REFERENCES

  1. Maldonado VR, Morales MG, et al. Carcinoma superficial de células transicionales de vejiga. Experiencia en 10 años. Rev Mex Urol 2001; 61: 13.

  2. Maldonado VR, Morales MG, et al. Carcinoma invasor de células transicionales de vejiga en el Hospital General “Dr. Manuel Gea González”. Experiencia en 10 años. Rev Mex Urol 2002; 62: 118-21.

  3. Zaragoza RI, Muñoz JA, et al. Utilidad clínica de p53 y antígeno de proliferación nuclear (pcna) en las biopsias tempranas de cáncer vesical superficial. Bol Col Mex Urol 1998; 15: 27-32.

  4. Fleshner N, Kapusta L, Ezer D, et al. P53 nuclear accumulation is not associate with decrease disease free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000; 164: 1177-82.

  5. Millar-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164: 680-4.

  6. Lee R, Droller M. Uroclinics North of America 2000; 1: 1-13.

  7. Carson D, Lois A. Cancer progression and P53. Lancet 1995; 346: 1009-11.

  8. Knowles M. The genetics of transitional cell carcinoma progress and potential clinical application. BJU International 1999; 84: 412-27.

  9. Caliskan M, Turkery B, Mansuroglu G. Nuclear accumulation of mutant p53 protein: possible predictor of failure of intravesical therapy in bladder cancer. BJU International 1997; 79: 373-7.

  10. 10.Keegan P, Lunec J, Neal D. P53 and p53 regulated genes in bladder cancer. BJU International 1998; 82: 710-20.

  11. 11.Adshead J, Kessling A, Ogden C. Genetic initiation and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. BJU International 1998; 82: 503-12.

  12. 12.Mydlo J, Weinstein R, Shah S, et al. Long term consequences from bladder perforation and/or violation in the presence of transitional cell carcinoma: results of a small series and a review of the literature. J Urol 1998; 153: 1128-32.

  13. 13.Gohji K, Nomi M, Okamoto M, et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999; 53: 308-13.

  14. 14.Hall M, Womakc S, Sagalowsky A, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30 years experience in 252 patients. Urology 1998; 52: 594-601.

  15. 15.Underwood M, Reeves J, Smith G, et al. Over expression of p53 protein and its significance for recurrent progressive bladder tumors. BJU International 1996; 77: 659-66.

  16. 16.Wu CS, Pollack A, Czerniak B, Chyle V, Zagars GK, Dinney CP, et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 1996; 47: 305.

  17. 17.Bernardini S, Billerey C, Martin M, et al. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 2001; 265: 42-6.

  18. 18.Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164: 685-9.

  19. 19.Norm DJ, et al. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder.

  20. 20.Slaton J, Benedict W, Dinney C. P53 bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 2001; 57: 852-9.




2020     |     www.medigraphic.com